This is a Phase 3, multi-center, North American, open-label, long-term, safety extension study for eligible subjects who received AR101 therapy in the ARC007 trial (NCT03126227) and completed the study.
This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.